Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results
10 août 2017 08h50 HE
|
Madrigal Pharmaceuticals, Inc.
- Completed patient enrollment in Phase 2 clinical study of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, for treatment of NASH - - Raised $35 million...
Associates in Cardiovascular Disease and Admera Health Unveiled a Health Economics Model at the 2017 National Lipid Association Conference Detailing the Cost Benefits of Genetic Testing for Familial Hypercholesterolemia
23 mai 2017 09h25 HE
|
Admera Health, LLC
SOUTH PLAINFIELD, N.J., May 23, 2017 (GLOBE NEWSWIRE) -- Admera Health, a molecular diagnostics company developing comprehensive genetic tests for risk assessment and early diagnosis of...
Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196
03 avr. 2017 07h30 HE
|
Madrigal Pharmaceuticals, Inc.
- MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, has the potential to treat NASH (non-alcoholic steatohepatitis) and familial hypercholesterolemia (FH) - -...
PCSK9 Barriers Survey Results Revealed at National Lipid Association Conference
07 févr. 2017 09h30 HE
|
National Lipid Association
PHOENIX, AZ--(Marketwired - February 07, 2017) - As part of its Spring Clinical Lipid Update (CLU) in Phoenix, the National Lipid Association (NLA) will reveal the results of its "Challenges in...
Admera Health Launches Molecular Test for Inherited Early Atherosclerosis Diagnosis and Risk
17 mars 2016 07h00 HE
|
Admera Health, LLC
SOUTH PLAINFIELD, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Admera Health (www.admerahealth.com), a commercial stage New Jersey based Precision Medicine and Digital Health company announced today the...
Aegerion Pharmaceuticals Observes Rare Disease Day
28 févr. 2013 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID(TM) (lomitapide) Capsules
07 janv. 2013 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
FDA Approves Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH)
24 déc. 2012 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...